

FOSTERA® GOLD PCV



DESCRIPTION

Fostera® Gold PCV is for the vaccination of healthy pigs 3 days of age or older against porcine circovirus 2 (PCV2). This ready-to-use combination vaccine delivers:

- **Broader protection against quickly evolving PCV2.**¹ With two PCV2 genotypes, Fostera Gold PCV has the broadest coverage available of any PCV2 vaccine on the market.
- **Demonstrated safety and efficacy against common PCV2 strains.** Fostera Gold PCV has demonstrated safety and protection against PCV2a, PCV2b and PCV2d.²⁻⁸
- **Long protection for pig health and your profitability.** Fostera Gold PCV is the longest-lasting PCV2 vaccine with a duration of immunity (DOI) of at least 23 weeks. This length of coverage can help reduce the risk of late breaks near finishing.
- **A safe, smooth vaccine.** Fostera Gold PCV was developed with the unique and smooth MetaStim® adjuvant that stimulates both cell-mediated and antibody-based immunity with minimal post-vaccination reactions.⁸
- **Continued productivity at the finishing stage.** PCV2 virus change and depressed immunity are unwanted surprises in pork production, especially at the finishing stage, risking pig health and productivity as well as farm profitability.

COMPARISON

When you use Fostera Gold PCV, you get broader and longer coverage against PCV2²⁻⁷ compared with other commercial vaccines, plus access to leading products for the pork industry, unmatched services of diagnostics, data analytics and training from Zoetis.

	Fostera® Gold PCV	Circumvent® G2	Ingelvac CircoFLEX®
Antigens included	PCV2a genotype PCV2b genotype	PCV2a genotype	PCV2a genotype
PCV2 DOI	At least 23 weeks	At least 20 weeks	At least four months (approximately 16 weeks)
Adjuvant formulation	MetaStim® adjuvant	Microsol Diluvac Forte adjuvant	ImpranFLEX water-based adjuvant

INDICATIONS

Fostera Gold PCV contains PCV2a and PCV2b, and has been shown to be effective for the vaccination of healthy pigs against PCV2, including PCV2 viremia, shedding of virus in feces, lymphoid colonization and lymphoid depletion.

For more information regarding efficacy and safety data, go to productdata.aphis.usda.gov.

FOSTERA® GOLD PCV



ADMINISTRATION

Shake well

Single-dose protocol: Administer a single 2-mL dose intramuscularly to healthy pigs 3 weeks of age or older.

Flexible, two-dose protocol: May also be given as two 1-mL doses administered intramuscularly three weeks apart to pigs 3 days of age* or older.

The optimal choice of the dosing regimen, including age at time of vaccination, will depend on farm circumstances.

*Field experience with PCV2 vaccines indicates waiting until 3 weeks of age to initiate a split-dose regimen may yield a better immune response, even though the vaccine is safe when given at a younger age.

PACKAGING

Fosterera® Gold PCV is available in the following presentations:

- 50-dose (100 mL) – SKU #10020020
- 250-dose (500 mL) – SKU #10020021

PRECAUTIONS

For veterinary use only.

Store at 2°-8°C (35°-46°F).

Do not freeze.

Use entire contents when first opened.

Do not vaccinate within 21 days before slaughter.

This product has not been tested in pregnant animals.

Contains gentamicin and thimerosal as preservatives.

The vaccine may induce mild to moderate transient local injection-site reactions following vaccination in 3-day-old piglets.

In case of allergic reaction, administer epinephrine.

Do not mix with other products.

In case of human exposure, contact a physician.

CONTACT INFORMATION

Technical inquiries should be directed to Zoetis Veterinary Services, **888-ZOETIS1** (888-963-8471) in the United States.

For additional information, contact your local veterinarian and Zoetis representative or visit ZoetisUS.com/FostereraGoldPCV.

¹Firth C, Charleston MA, Duffy S, Shapiro B, Holmes EC. Insights into the evolutionary history of an emerging livestock pathogen: porcine circovirus 2. *J Virol*. 2009;83(24):12813-12821.

²Data on file, Study Report No. B822R-US-14-325, Zoetis Inc.

³Data on file, Study Report No. B822R-US-16-582, Zoetis Inc.

⁴Data on file, Study Report No. B825R-US-16-667, Zoetis Inc.

⁵Data on file, Study Report No. B822R-US-15-557, Zoetis Inc.

⁶Data on file, Study Report No. B824R-US-15-451, Zoetis Inc.

⁷Data on file, Study Report No. B824R-US-13-118, Zoetis Inc.

⁸Data on file, Study Report No. B921R-US-16-609, Zoetis Inc.